Abstract
Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.
| Original language | English |
|---|---|
| Pages (from-to) | 1838-1845 |
| Number of pages | 8 |
| Journal | European Heart Journal |
| Volume | 26 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - Sep 2005 |
Fingerprint
Keywords
- CD34
- Endothelial progenitor cells
- Granulocyte-colony stimulating factor
- Myocardial infarction
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans : Clinical and angiographic safety profile. / Valgimigli, Marco; Rigolin, Gian Matteo; Cittanti, Corrado; Malagutti, Patrizia; Curello, Salvatore; Percoco, Gianfranco; Bugli, Anna Maria; Della Porta, Matteo; Bragotti, Letizia Zenone; Ansani, Lucia; Mauro, Endri; Lanfranchi, Arnalda; Giganti, Melchiore; Feggi, Luciano; Castoldi, Gianluigi; Ferrari, Roberto.
In: European Heart Journal, Vol. 26, No. 18, 09.2005, p. 1838-1845.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans
T2 - Clinical and angiographic safety profile
AU - Valgimigli, Marco
AU - Rigolin, Gian Matteo
AU - Cittanti, Corrado
AU - Malagutti, Patrizia
AU - Curello, Salvatore
AU - Percoco, Gianfranco
AU - Bugli, Anna Maria
AU - Della Porta, Matteo
AU - Bragotti, Letizia Zenone
AU - Ansani, Lucia
AU - Mauro, Endri
AU - Lanfranchi, Arnalda
AU - Giganti, Melchiore
AU - Feggi, Luciano
AU - Castoldi, Gianluigi
AU - Ferrari, Roberto
PY - 2005/9
Y1 - 2005/9
N2 - Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.
AB - Aims: There is increasing evidence that stem cell (SC) mobilization to the heart and their differentiation into cardiac cells is a naturally occurring process. We sought to assess the safety and feasibility of granulocyte-colony stimulating factor (G-CSF) administration in humans to enhance SC mobilization and left ventricle (LV) injury repair during myocardial infarction (MI). Methods and results: Twenty patients with STEMI (mean age, 61 ± 10 years), of whom 14 were submitted to primary percutaneous coronary intervention, were randomized to G-CSF (5 μg/kg/day s.c. for 4 consecutive days) or placebo. At entry and then at months 3 and 6, 99mTc-sestamibi gated-SPECT was performed to estimate extension of perfusion defect (PD) and LV function. The study drug was well tolerated and induced a significant increase of white blood count, CD34+ cells, and CD34+ cells coexpressing AC133 and VEGFR-2. At follow-up, treated and placebo groups did not differ for the angiographic coronary late loss and showed a similar pattern of PD recovery, whereas in the former at 6 months LVEF and especially LVEDV tended to be relatively higher (P = 0.068) and lower (P = 0.054), respectively. Conclusion G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34+ and CD34+AC133+VEGFR2+ cell mobilization.
KW - CD34
KW - Endothelial progenitor cells
KW - Granulocyte-colony stimulating factor
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=24344446509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24344446509&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehi289
DO - 10.1093/eurheartj/ehi289
M3 - Article
C2 - 15860518
AN - SCOPUS:24344446509
VL - 26
SP - 1838
EP - 1845
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 18
ER -